ClinTec ceo receives Honorary Doctorate
For her contribution to life sciences industry
This honorary doctorate was awarded in recognition of Dr Buttar’s contribution to the life sciences Industry over 20 years and for the foundation and development of ClinTec International.
Professor Seamus McDaid, principal and vice chancellor of the University of the West of Scotland, said: ‘We are delighted to award Dr Buttar with an Honorary Doctorate. As chief executive of ClinTec International, she is one of the country’s most important business leaders, making a hugely important contribution to the Scottish economy.’
At the graduation ceremony, which took place in Paisley, Dr Buttar said: ‘The University has created an exceptional pool of local and international graduates and I am honoured to come back here after 20 years and accept this degree. These graduates here today have successfully completed one chapter of their lives and as they open the next one their learning should never stop.
‘In the current challenging times, graduates should seek local as well as global opportunities, look to do something they feel passionate about, be even more determined than ever before to succeed and then further success will be in their hands. The University and its excellent staff have prepared them well for the challenges that lie ahead.
‘I feel honoured and privileged to join the Court and Senate today in recognising and celebrating in some of Scotland’s academic achievements.’
Dr Buttar has also been named as the Ernst & Young Entrepreneur of the Year for Scotland and the Institute of Directors’ Regional Director of the Year for the West of Scotland.
You may also like
Manufacturing
Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility
The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables
Research & Development
Simris Biologics secures €200K funding to develop microcystin-based payloads for antibody-drug conjugates
The Berlin-based subsidiary will use the grant to advance the KlicMic R&D programme, creating targeted microcystin payloads for ADCs that aim to improve cancer therapy efficacy whilst reducing side effects
Research & Development
Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness
The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production